レボサルブタモール

(-)-Salbutamol

HCID 123600CAS 34391-04-3

基本情報

標準SMILES
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1
InChIKey
NDAUXUAQIAJITI-LBPRGKRZSA-N
分子式
C13H21NO3
平均分子量
239.31 g/mol
単同位体質量
239.15214353

概要

(R)-salbutamol is an albuterol.

名称と識別子

優先名称
(-)-Salbutamol
IUPAC
4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenol
現地名
レボサルブタモール
英語名
Levalbuterol
分子式
C13H21NO3
分子量
239.31

名称と別名

LevalbuterolLevosalbutamol(-)-Salbutamol34391-04-3(R)-salbutamol(-)-AlbuterolR-Salbutamol4-[(1R)-2-(tert-butylamino)-1-hydroxyethyl]-2-(hydroxymethyl)phenolEDN2NBH5SSASF-1096CHEBI:8746DTXSID80187964
名称をさらに表示
レバルブテロール(R)-1-[4-ヒドロキシ-3-(ヒドロキシメチル)フェニル]-2-(1,1-ジメチルエチルアミノ)エタノール2-(ヒドロキシメチル)-4-[(R)-1-ヒドロキシ-2-[(1,1-ジメチルエチル)アミノ]エチル]フェノール(αR)-α-[(tert-ブチルアミノ)メチル]-4-ヒドロキシ-1,3-ベンゼンジメタノール(R)-1-(4-ヒドロキシ-3-ヒドロキシメチルフェニル)-2-(1,1-ジメチルエチルアミノ)エタノール(R)-1-(4-ヒドロキシ-3-ヒドロキシメチルフェニル)-2-tert-ブチルアミノエタノール(R)-アルブテロール(R)-4-ヒドロキシ-3-ヒドロキシメチル-α-[(tert-ブチルアミノ)メチル]ベンジルアルコール(αR)-α-(tert-ブチルアミノメチル)-4-ヒドロキシ-3-(ヒドロキシメチル)ベンゼンメタノール(R)-サルブタモールレボサルブタモール(-)-サルブタモール(R)-4-ヒドロキシ-3-(ヒドロキシメチル)-α-[[(tert-ブチル)アミノ]メチル]ベンジルアルコール4-[(1R)-2-(tert-ブチルアミノ)-1-ヒドロキシエチル]-2-(ヒドロキシメチル)フェノールLEVALBUTEROL HCLSalbutamolr-albuterolLevalbutreol(L)-ALBUTEROLR-SALBUTAMOL HCLLEVOSALBUTEROLHCL
levosalbutamolum4-((1R)-2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenolAlbuterol (r)-Levalbuterol InhalationRefChem:56698Hydrochloride, LevalbuterolHydrochloride, LevosalbutamolDTXCID40110455

データベース識別子

CAS
34391-04-3
PubChem CID
123600
DTXSID
DTXSID80187964
ChEMBL
CHEMBL1002
ChEBI
CHEBI:8746
UNII
EDN2NBH5SS
EC Number
608-983-3
Nikkaji
J428.072E

物性

構造計算による物性

XLogP
0.3
極性表面積
72.7 Ų
水素結合供与体数
4
水素結合受容体数
4
回転可能結合数
5
重原子数
17

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human DrugsBreast Feeding; Lactation; Milk, Human; Anti-Asthmatic Agents; Bronchodilator Agents; Beta Adrenergic Agonists
Collision Cross Section153.47 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

沸点
433.5 · 433.5±40.0 °C(Predicted)
比重(密度)
1.152 · 1.152±0.06 g/cm3(Predicted)
酸解離定数(Pka)
9.99 · 9.99±0.31(Predicted)
InChI
InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3/t12-/s3
InChIKey
NDAUXUAQIAJITI-PLAQIDKDNA-N
SMILES
C1(=CC=C(O)C(CO)=C1)[C@@H](O)CNC(C)(C)C |&1:9,r|

安全と法規制

毒性情報

Exposure RoutesSystemic absorption is rapid following aerosol administration.
Toxicity Summary · 1 件

Salbutamol is a beta(2)-adrenergic agonist and thus it stimulates beta(2)-adrenergic receptors. Binding of albuterol to beta(2)-receptors in the lungs results in relaxation of bronchial smooth muscles. It is believed that salbutamol increases cAMP production by activating adenylate cyclase, and the actions of salbutamol are mediated by cAMP. Increased intracellular cyclic AMP increases the activity of cAMP-dependent protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations. A lowered intracellular calcium concentration leads to a smooth muscle relaxation and bronchodilation. In addition to bronchodilation, salbutamol inhibits the release of bronchoconstricting agents from mast cells, inhibits microvascular leakage, and enhances mucociliary clearance.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataLD<sub>50</sub>=1100 mg/kg (orally in mice)

安全データ

risk_code
22
hazard_code
Xn
safety_code
36

化学と産業

薬理情報

Protein Bindingplasma protein binding is relatively low.
PharmacodynamicsIt acts by relaxing smooth muscle in the bronchial tubes to increase air flow and relieve acute shortness of breath.
Mechanism of Action · 1 件

β2 adrenergic receptors on airway smooth muscle are Gs coupled and their activation by levosalbutamol leads to activation of adenylate cyclase and to an increase in the intracellular concentration of 3',5'-cyclic adenosine monophosphate (cyclic AMP). Increased cyclic AMP activates protein kinase A which itself inhibits the phosphorylation of myosin produces lower intracellular ionic calcium concentrations, inducing muscle relaxation. Increased cyclic AMP concentrations are also associated with the inhibition of the release of mediators from mast cells in the airways, potentially contributing to its benefit in asthma attacks.

Biological Half-Life3.3 - 4 hours
Metabolism/Metabolites · 2 件

Pure (R)-salbutamol formulation known as levosalbutamol is metabolised up to 12 times faster than (S)-salbutamol by intestine.

Hydrolyzed by esterases in tissue and blood to the active compound colterol. The drug is also conjugatively metabolized to salbutamol 4'-O-sulfate. Route of Elimination: Approximately 72% of the inhaled dose is excreted in the urine within 24 hours, 28% as unchanged drug and 44% as metabolite. Half Life: 1.6 hours

FDA Pharmacological Classification · 6 件

EDN2NBH5SS

LEVALBUTEROL

Mechanisms of Action [MoA] - Adrenergic beta2-Agonists

Established Pharmacologic Class [EPC] - beta2-Adrenergic Agonist

Levalbuterol is a beta2-Adrenergic Agonist. The mechanism of action of levalbuterol is as an Adrenergic beta2-Agonist.

LEVALBUTEROL

用途と製造

UsesFor symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
応用分野 · 2 件

説明Levalbuterol was launched in the US for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. It is the single R-enantiomer version of racemic albuterol (salbutamol) marketed for more than 30 years as a mainstay in the treatment of asthma. The R-isomer can be obtained with an excellent optical purity by enantiomeric purification based on the separation of diastereomeric tartrates. This isomer retains solely the desired bronchodilating effect of the racemic mixture due to a potent agonistic effect on β2-adrenoceptors, with a lower incidence of β- mediated side effects such as pulse rate increase, tremor and decrease in blood glucose and potassium levels. A pivotal clinical trial with two doses of levalbuterol and racemic albuterol, given by nebulization, demonstrated a greater improvement in lung function for the pure enantiomer levalbuterol.

使用(R)-Salbutamol is used in composition and methods to reduce beta-agonist-mediated tachyphylaxis.

サプライヤー36 社

Suzhou ARTK Medchem Co., Ltd.+86-18168183658 · [email protected]
Baoji Guokang Healthchem co.,ltd+8615604608665 15604608665 · [email protected]
LGM Pharma1-(800)-881-8210 · [email protected]
广东云星生物技术有限公司0751-18902340975/189023400307 18902340307 · [email protected]
InvivoChem中国13549236410 · [email protected]

関連反応

3 件

関連ノート

読み込み中…